MX2013010342A - Uso de dosis bajas de il-2 para tratar transtornos inflamatorios o relacionados con la autoinmunidad. - Google Patents

Uso de dosis bajas de il-2 para tratar transtornos inflamatorios o relacionados con la autoinmunidad.

Info

Publication number
MX2013010342A
MX2013010342A MX2013010342A MX2013010342A MX2013010342A MX 2013010342 A MX2013010342 A MX 2013010342A MX 2013010342 A MX2013010342 A MX 2013010342A MX 2013010342 A MX2013010342 A MX 2013010342A MX 2013010342 A MX2013010342 A MX 2013010342A
Authority
MX
Mexico
Prior art keywords
low dose
treating autoimmune
inflammatory disorders
autoimmune
relates
Prior art date
Application number
MX2013010342A
Other languages
English (en)
Other versions
MX347324B (es
Inventor
David Klatzmann
David Saadoun
Patrice Cacoub
Michèle Rosenzwajg
Elaine Piaggio
Gilbert Bensimon
Claude Bernard
Original Assignee
Assistance Publique Hôpitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44244599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013010342(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Assistance Publique Hôpitaux De Paris filed Critical Assistance Publique Hôpitaux De Paris
Publication of MX2013010342A publication Critical patent/MX2013010342A/es
Publication of MX347324B publication Critical patent/MX347324B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere tratamientos novedosos basados en IL-2 para tratar enfermedades autoinmunes e inflamatorias. De forma más específica, la presente invención se refiere al uso de una dosis baja de IL-2 para el tratamiento de la diabetes de tipo I y otras enfermedades autoinmunes y/o inflamatorias.
MX2013010342A 2011-03-11 2012-03-09 Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad. MX347324B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451663P 2011-03-11 2011-03-11
EP11305269 2011-03-11
PCT/EP2012/054174 WO2012123381A1 (en) 2011-03-11 2012-03-09 Use of low dose il-2 for treating autoimmune - related or inflammatory disorders

Publications (2)

Publication Number Publication Date
MX2013010342A true MX2013010342A (es) 2014-03-05
MX347324B MX347324B (es) 2017-04-19

Family

ID=44244599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010342A MX347324B (es) 2011-03-11 2012-03-09 Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.

Country Status (12)

Country Link
US (1) US20230149512A1 (es)
EP (3) EP2683395B1 (es)
JP (2) JP6054889B2 (es)
KR (1) KR102220006B1 (es)
CN (2) CN109432407A (es)
AU (4) AU2012228418B2 (es)
CA (1) CA2828657A1 (es)
DK (2) DK2683395T3 (es)
ES (1) ES2693645T3 (es)
MX (1) MX347324B (es)
PL (2) PL3443979T3 (es)
WO (1) WO2012123381A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5766124B2 (ja) 2009-01-21 2015-08-19 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
EP2943253B1 (en) * 2013-01-09 2021-10-20 University Of Miami Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein and il-2
EP3013355B1 (en) * 2013-06-25 2019-08-07 ICM - Institut du Cerveau et da la Moelle Epinière Il-2 for use in treating alzheimer disease and related disorders
HUE041530T2 (hu) 2014-02-06 2019-05-28 Hoffmann La Roche Interleukin-2 fúziós fehérjék és alkalmazásaik
EP2918285A1 (en) * 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 for treating food allergy
WO2015162124A1 (en) * 2014-04-22 2015-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnostic of an autoimmune disease
CN104189892A (zh) * 2014-08-22 2014-12-10 北京大学人民医院 低剂量白细胞介素2在免疫相关性疾病治疗中的应用
CN107106876B (zh) * 2014-10-09 2021-06-11 丹娜法伯癌症研究院 用于治疗免疫失调的多次-可变il-2剂量方案
CN104459129A (zh) * 2015-01-05 2015-03-25 复旦大学附属华山医院 一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒
US10851144B2 (en) 2015-04-10 2020-12-01 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US12023367B2 (en) 2015-06-19 2024-07-02 University Of Louisville Research Foundation, Inc. Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection
EP3347036A1 (en) * 2015-09-10 2018-07-18 Assistance Publique - Hôpitaux de Paris Use of interleukin 2 for treating spondyloarthritis
US11191743B2 (en) * 2016-01-11 2021-12-07 Dignity Health Modulators of zinc activated cation channel
US10961310B2 (en) 2017-03-15 2021-03-30 Pandion Operations, Inc. Targeted immunotolerance
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
JP7271539B2 (ja) * 2017-11-14 2023-05-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル リンホトキシンアルファ遺伝子について遺伝的に改変された調節性ｔ細胞及びその使用
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
CR20200546A (es) * 2018-05-21 2021-05-18 Nektar Therapeutics ESTIMULADOR SELECTIVO TREG RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS
WO2020007937A1 (en) * 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
US20200282013A1 (en) * 2019-03-08 2020-09-10 DrugCendR, Inc. Low-dose cytokine co-administered with irgd for treating cancer
CN109999179A (zh) * 2019-05-08 2019-07-12 山东省分析测试中心 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. ANTI-MADCAM IMMUNE TOLERANCE
CN110251659A (zh) * 2019-07-03 2019-09-20 安徽省立医院 一种小剂量白细胞介素2在制备治疗慢性痛风药物中的应用
TW202118774A (zh) 2019-07-26 2021-05-16 美商威特拉公司 介白素-2藥劑及其用途
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
TW202146041A (zh) 2020-03-06 2021-12-16 尼姆大學醫學中心 用於肌肉萎縮性脊髓側索硬化症之治療的低劑量人類介白素-2
TW202237171A (zh) 2020-12-04 2022-10-01 美商威特拉公司 使用介白素-2藥劑之方法
CN113304248B (zh) * 2021-07-01 2023-01-03 北京大学人民医院 Il-2在制备缓解糖皮质激素类药物副作用的药物中的应用
CN115607653B (zh) * 2022-07-09 2023-09-26 曹霞 低剂量白介素2在治疗孤独症中的应用
WO2024121173A1 (en) 2022-12-05 2024-06-13 Centre Hospitalier Universitaire De Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
CN115779072B (zh) * 2023-02-06 2023-10-17 北京大学第三医院（北京大学第三临床医学院） 一种包含低浓度il-2的用于治疗干眼的药物组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4656132A (en) 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
EP0262802A3 (en) * 1986-09-01 1990-01-31 Takeda Chemical Industries, Ltd. Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus
JPS63183538A (ja) * 1986-09-01 1988-07-28 Takeda Chem Ind Ltd 関節リウマチまたは全身性エリテマト−デスの改善，治療剤
US5466447A (en) 1988-06-29 1995-11-14 Amgen Inc. Method for treating psoriasis
WO1991014444A1 (en) 1990-03-19 1991-10-03 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
FR2769505B1 (fr) 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
GB9724838D0 (en) 1997-11-26 1998-01-21 Franks Christopher R Compositions
AU2002258606A1 (en) * 2001-03-30 2002-10-15 Mayo Foundation For Medical Education And Research Aerosol administration of interleukin-2 liposomes
CA2478245A1 (en) * 2002-03-08 2003-09-18 Monsanto Technology Llc Treatment and prevention of inflammatory disorders
DE60233576D1 (de) * 2002-12-02 2009-10-15 Innate Pharma Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
ES2432141T3 (es) 2005-01-27 2013-11-29 Novartis Vaccines And Diagnostics, Inc. Procedimientos para tratar carcinoma de células renales
WO2009112502A1 (en) 2008-03-13 2009-09-17 Biotest Ag Agent for treating disease
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
WO2010049438A2 (en) 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
JP5766124B2 (ja) 2009-01-21 2015-08-19 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物

Also Published As

Publication number Publication date
AU2016273847B2 (en) 2018-04-19
ES2693645T3 (es) 2018-12-13
PL2683395T3 (pl) 2019-04-30
EP3443979B1 (en) 2020-05-27
JP6054889B2 (ja) 2016-12-27
AU2012228418A1 (en) 2013-09-05
CA2828657A1 (en) 2012-09-20
CN103732241A (zh) 2014-04-16
AU2018206705B2 (en) 2020-03-19
JP7561893B2 (ja) 2024-10-04
EP2683395B1 (en) 2018-08-01
EP2683395A1 (en) 2014-01-15
AU2018206705A1 (en) 2018-08-02
PL3443979T3 (pl) 2020-11-16
JP2014510725A (ja) 2014-05-01
AU2016273847A1 (en) 2017-01-05
EP3766513A1 (en) 2021-01-20
DK3443979T3 (da) 2020-08-24
DK2683395T3 (en) 2018-11-19
KR102220006B1 (ko) 2021-02-24
AU2020204023B2 (en) 2022-06-02
AU2020204023A1 (en) 2020-07-09
US20230149512A1 (en) 2023-05-18
AU2016273847A2 (en) 2017-02-02
KR20140053869A (ko) 2014-05-08
MX347324B (es) 2017-04-19
AU2012228418B2 (en) 2016-09-29
WO2012123381A1 (en) 2012-09-20
EP3443979A1 (en) 2019-02-20
JP2023029565A (ja) 2023-03-03
CN109432407A (zh) 2019-03-08

Similar Documents

Publication Publication Date Title
MX347324B (es) Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.
CL2015001241A1 (es) Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)
EP4233545A3 (en) Synergistic bacterial compositions and methods of production and use thereof
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
MX2015008114A (es) Derivados de exendina-4.
MY170713A (en) Treatment protocol of diabetes type 2
MX2014015423A (es) Analogos de peptido de exedina-4.
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
NZ707139A (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
MX2015015249A (es) Peptidos terapeuticos.
EA201590359A1 (ru) Лечение ревматоидного артрита
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2013003309A (es) Compuestos de benzamida sustituidos.
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
MX2012013735A (es) Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.
MX2012000949A (es) Terapias de combinacion con moduladores de ck2.
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
NZ610891A (en) Cd89 activation in therapy
SG179203A1 (en) Novel arylated camphenes, processes for their preparation and uses thereof
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX366636B (es) Nuevo derivado de un análogo de insulina.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
PH12015500322A1 (en) Tris(hetero)arylpyrazoles and use thereof
NZ704280A (en) Baclofen and acamprosate based therapy of macular degeneration disorders

Legal Events

Date Code Title Description
FG Grant or registration